 Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates are expected in the 2nd half of 2022. Poseida established a deal with Roche for allogeneic therapies targeting hematological malignancies; upfront payment of 110 million and potential to earn an aggregate of 6 billion in milestone payments. 